EA201600012A1 - Способ профилактики и/или лечения сердечно-сосудистых заболеваний - Google Patents

Способ профилактики и/или лечения сердечно-сосудистых заболеваний

Info

Publication number
EA201600012A1
EA201600012A1 EA201600012A EA201600012A EA201600012A1 EA 201600012 A1 EA201600012 A1 EA 201600012A1 EA 201600012 A EA201600012 A EA 201600012A EA 201600012 A EA201600012 A EA 201600012A EA 201600012 A1 EA201600012 A1 EA 201600012A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prevention
treatment
cardiovascular diseases
statin
acetylsalicylic acid
Prior art date
Application number
EA201600012A
Other languages
English (en)
Other versions
EA028969B1 (ru
Inventor
Пабло Мартин Санс
Хавьер Урбано Уртадо
Original Assignee
Феррер Интернасионал, С.А.
Фундасион Сентро Насионал де Инвестигасионес Кардиоваскуларес Карлос III
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48569993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201600012(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Феррер Интернасионал, С.А., Фундасион Сентро Насионал де Инвестигасионес Кардиоваскуларес Карлос III filed Critical Феррер Интернасионал, С.А.
Publication of EA201600012A1 publication Critical patent/EA201600012A1/ru
Publication of EA028969B1 publication Critical patent/EA028969B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Данное изобретение относится к фармацевтическому составу, включающему ингибитор редуктазы ГМГ-КоА, в частности статин, и ацетилсалициловую кислоту таким образом, чтобы минимизировать взаимодействие ацетилсалициловой кислоты со статином, для профилактики или лечения сердечно-сосудистых заболеваний.
EA201600012A 2013-06-06 2014-06-05 Способ профилактики и/или лечения сердечно-сосудистых заболеваний EA028969B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13170909.9A EP2810644A1 (en) 2013-06-06 2013-06-06 Oral formulation for the treatment of cardiovascular diseases
PCT/EP2014/061735 WO2014195421A1 (en) 2013-06-06 2014-06-05 Oral formulation for the treatment of cardiovascular diseases

Publications (2)

Publication Number Publication Date
EA201600012A1 true EA201600012A1 (ru) 2016-07-29
EA028969B1 EA028969B1 (ru) 2018-01-31

Family

ID=48569993

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201600012A EA028969B1 (ru) 2013-06-06 2014-06-05 Способ профилактики и/или лечения сердечно-сосудистых заболеваний

Country Status (42)

Country Link
US (1) US10617699B2 (ru)
EP (3) EP2810644A1 (ru)
JP (1) JP6151854B2 (ru)
KR (1) KR101839665B1 (ru)
CN (2) CN104224804A (ru)
AP (1) AP2015008882A0 (ru)
AR (1) AR096350A1 (ru)
AU (1) AU2014276883B2 (ru)
BR (1) BR112015030350B1 (ru)
CA (1) CA2912350C (ru)
CL (1) CL2015003561A1 (ru)
CR (1) CR20150635A (ru)
CU (1) CU24326B1 (ru)
CY (1) CY1118766T1 (ru)
DK (1) DK2986281T3 (ru)
DO (1) DOP2015000296A (ru)
EA (1) EA028969B1 (ru)
EC (1) ECSP15050273A (ru)
ES (1) ES2620078T3 (ru)
GE (1) GEP201706743B (ru)
HK (1) HK1204562A1 (ru)
HU (1) HUE033458T2 (ru)
IL (1) IL242569B (ru)
MA (1) MA38699B1 (ru)
MD (1) MD4475C1 (ru)
MX (1) MX347801B (ru)
MY (1) MY181272A (ru)
NI (1) NI201500171A (ru)
NZ (1) NZ714707A (ru)
PE (1) PE20160051A1 (ru)
PH (1) PH12015502706B1 (ru)
PL (1) PL2986281T3 (ru)
PT (1) PT2986281T (ru)
RS (1) RS55786B1 (ru)
SA (1) SA515370243B1 (ru)
SG (1) SG11201509353QA (ru)
SI (1) SI2986281T1 (ru)
TN (1) TN2015000501A1 (ru)
TW (1) TWI630928B (ru)
UA (1) UA113806C2 (ru)
WO (1) WO2014195421A1 (ru)
ZA (1) ZA201508452B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3283058T3 (pl) * 2015-04-16 2023-03-20 Novartis Ag Tabletka rybocyklibu
CN111135149B (zh) * 2018-11-04 2021-05-11 张家港市中医医院 一种瑞舒伐他汀钙片及其制备方法
CN110693929A (zh) * 2019-09-09 2020-01-17 安徽中医药大学 复方药物组份在治疗脑梗死恢复期中的应用
EP4299063B1 (en) * 2022-06-30 2024-05-01 Ferrer Internacional, S.A. Oral capsules comprising atorvastatin tablets showing suitable dissolution profile and bioavailability

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
AU570021B2 (en) 1982-11-22 1988-03-03 Novartis Ag Analogs of mevalolactone
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0904082A4 (en) * 1996-04-17 2001-09-26 Merck & Co Inc COMBINATION THERAPY TO REDUCE THE RISKS OF HEART CIRCULAR DISEASES
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
KR20030025903A (ko) 2000-02-10 2003-03-29 비피에스아이 홀딩스, 인코포레이션. 아크릴 장용 코팅 조성물
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20040115265A1 (en) * 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
WO2004080488A2 (de) 2003-03-10 2004-09-23 Bayer Healthcare Ag Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase
CN1822820A (zh) * 2003-07-28 2006-08-23 雷迪实验室有限公司 心血管疾病的治疗和预防
ES2395724T3 (es) 2003-08-20 2013-02-14 Shionogi & Co., Ltd. Nueva composición de recubrimiento
AU2004293178B8 (en) 2003-11-26 2009-01-08 Novartis Ag Organic compounds
EP1784193A4 (en) * 2004-06-28 2009-09-23 Smith Howard J & Ass Pty Ltd COMPOSITION AND METHOD FOR THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS
EP1856032A1 (en) 2005-03-11 2007-11-21 Speedel Experimenta AG Heterocyclic-substituted alkanamides useful as renin inhibitors
US20070009591A1 (en) 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
US20070116756A1 (en) 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US7427414B2 (en) 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
CN101176725A (zh) * 2006-07-14 2008-05-14 兰贝克赛实验室有限公司 辛伐他汀和阿司匹林的稳定剂型
PL2120878T3 (pl) * 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
US20120015032A1 (en) 2007-08-13 2012-01-19 Hanall Pharmaceutical Company, Ltd. Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
US20090076062A1 (en) 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
WO2009118359A2 (en) * 2008-03-28 2009-10-01 Ferrer Internacional S.A. Capsule for the prevention of cardiovascular diseases
CN102480954B (zh) * 2009-02-11 2015-03-18 卡帝拉药物有限公司 用于动脉粥样硬化的稳定的药物组合物
NZ596064A (en) * 2009-04-30 2014-03-28 Reddy’S Lab Ltd Dr Fixed dose drug combination formulations
JP2013510145A (ja) 2009-11-09 2013-03-21 メディヴィル・アクチエボラーグ １，３−オキサゾリジン化合物およびレニン阻害剤としてのそれらの使用方法
KR101193493B1 (ko) * 2010-02-02 2012-10-22 한미사이언스 주식회사 소수성 첨가제가 함유된 분리막으로 코팅된 아스피린 및 ＨＭＧ?ＣｏＡ 환원효소 억제제를 포함하는 복합제제
CN102049049A (zh) * 2010-11-27 2011-05-11 王定豪 包含阿司匹林盐和他汀类药物的药物组合物

Also Published As

Publication number Publication date
EP2986281A1 (en) 2016-02-24
TN2015000501A1 (en) 2017-04-06
HUE033458T2 (en) 2017-12-28
PH12015502706A1 (en) 2016-03-14
GEP201706743B (en) 2017-09-25
EP2810644A1 (en) 2014-12-10
NI201500171A (es) 2019-05-07
PL2986281T3 (pl) 2017-06-30
CN113143888A (zh) 2021-07-23
DK2986281T3 (en) 2017-04-03
CR20150635A (es) 2016-06-10
DOP2015000296A (es) 2016-12-30
MX2015015753A (es) 2016-08-03
JP6151854B2 (ja) 2017-06-21
ECSP15050273A (es) 2017-07-31
US20160106763A1 (en) 2016-04-21
AU2014276883A1 (en) 2015-11-26
KR20160014622A (ko) 2016-02-11
CY1118766T1 (el) 2017-07-12
PT2986281T (pt) 2017-03-29
KR101839665B1 (ko) 2018-03-16
CN104224804A (zh) 2014-12-24
MD20160001A2 (ru) 2016-05-31
CU20150173A7 (es) 2016-06-29
MA38699A1 (fr) 2017-01-31
JP2016520135A (ja) 2016-07-11
EP2986281B1 (en) 2016-12-21
SA515370243B1 (ar) 2016-09-19
SG11201509353QA (en) 2015-12-30
PH12015502706B1 (en) 2016-03-14
US10617699B2 (en) 2020-04-14
AP2015008882A0 (en) 2015-11-30
EP3175849A1 (en) 2017-06-07
UA113806C2 (xx) 2017-03-10
MA38699B1 (fr) 2017-09-29
NZ714707A (en) 2019-04-26
PE20160051A1 (es) 2016-01-25
RS55786B1 (sr) 2017-07-31
CA2912350C (en) 2017-04-04
CA2912350A1 (en) 2014-12-11
MD4475C1 (ru) 2017-11-30
WO2014195421A1 (en) 2014-12-11
ZA201508452B (en) 2017-02-22
CU24326B1 (es) 2018-03-13
MX347801B (es) 2017-05-15
MY181272A (en) 2020-12-21
MD4475B1 (ru) 2017-04-30
EA028969B1 (ru) 2018-01-31
BR112015030350A2 (pt) 2017-07-25
TWI630928B (zh) 2018-08-01
SI2986281T1 (sl) 2017-07-31
ES2620078T3 (es) 2017-06-27
IL242569B (en) 2018-12-31
HK1204562A1 (en) 2015-11-27
CL2015003561A1 (es) 2016-06-10
AU2014276883B2 (en) 2017-04-20
AR096350A1 (es) 2015-12-23
TW201536357A (zh) 2015-10-01
BR112015030350B1 (pt) 2022-11-29

Similar Documents

Publication Publication Date Title
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
UA118177C2 (uk) Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
BR112015026307A2 (pt) heterociclo bicíclicos como inibidores de fgfr
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
EA201490688A1 (ru) 2-тиопиримидиноны
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
EA201300688A1 (ru) Новая форма введения ингибитора энкефалиназы
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
BR112018014247A2 (pt) inibição de reação alérgica usando um inibidor il-33
PE20142182A1 (es) Inhibidores de iap
EA201790484A1 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена
EA201600012A1 (ru) Способ профилактики и/или лечения сердечно-сосудистых заболеваний
EA201491496A1 (ru) Ингибиторы c-концевого домена hsp90
EA201790699A1 (ru) Стабилизированные производные адреномедуллина и их применение
EA201890419A1 (ru) ОТСЕЛЕКТИРОВАННЫЙ АМИД γ-ГИДРОКСИМАСЛЯНОЙ КИСЛОТЫ И ЕГО ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗЛОУПОТРЕБЛЕНИЯ АЛКОГОЛЕМ
TW201613598A (en) Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors
SG10202000597UA (en) PHARMACEUTICAL COMPOSITION COMPRISING AN HMG-CoA REDUCTASE INHIBITOR AND AN ACE INHIBITOR
EA201792093A1 (ru) 2-тиопиримидиноны
MX2019011567A (es) Estatina para la prevención/reducción de daño relacionado con isquemia.
EA201201529A1 (ru) Комбинация ингибиторов ксантиноксидазы и статинов и ее применение
LV14963A (lv) Endoteliālās disfunkcijas korektors
EA201301341A1 (ru) Фармацевтическая композиция, обладающая панкреопротекторным действием, её применение для профилактики или лечения панкреатита и способ профилактики и лечения панкреатита
EA202091923A1 (ru) Замещенные трициклические соединения как ингибиторы fgfr